

Program Grid			
Date/ Day	Topic	Time	
15th December/ Thursday	NGO Workshop	10:00-02:00	
	Nurses Workshop	03:00-06:00	
	Radiology workshop	06:30-08:30	
16th December/ Friday	Main Conference	09:00-06:00	
17th December/ Saturday	Main Conference	09:00-06:00	
	Geriatric	9.00-3 pm	
	Molecular Oncology & Pathology	03:00-08:00	
18th December/ Sunday	Main Conference	10:00-02:00	
	Radiation Workshop	09:00-12:00	
	Onco Pulmo	12:30-03:00	
	Geriatric	9am-12.00	
	Palliative Workshop	12:00-02:00	
NGO Workshop			
15 December, Thursday, 10 AM to 2 PM			
Time	Topic	Faculty	Details
09.30 AM – 10.00 AM	Registration and Refreshments		
10.00 AM – 10.10 AM	Welcome address	Ms. Bhavisha Sanadhya, Mr. Sanjeev Sharma	Welcoming participants, ground rules and sharing the agenda of the workshop
10.10 AM – 10.30 AM	Lung Connect: Getting stronger with partnerships and preparing for the future	Dr. Kumar Prabhash	Journey of Lung Connect so far and Key milestones in the last one year.
10.30 AM – 11.30 AM	<p>Panel Discussion:</p> <p>a. What are the needs of Lung Cancer patients & caregivers?</p> <p>b. How can a patient/ caregiver be self-reliant and act as a resource to fellow patients/ caregivers?</p>	<p>Survivor/Caregiver / Medical experts</p> <p>Chairperson: Dr. Vijay Patil Dr. Shubha Maudgal</p> <p>Moderator : Ms. Usha Banerjee</p> <p>Panelists: Dr. Akhil Kapoor Dr. Amit Kumar Ms. Adriya Dey Mr. Chandu Parab Mr. Ravi Prakash Dr. S H Jafri Dr. Sameer Nanaware Ms. Savita Goswami Mr. Vikas Hawaldar Dr Prakash Fernandes</p>	<p>Patient's Perspective:</p> <ul style="list-style-type: none"> - Disease Awareness/ Treatment/ Navigation - Psychological Health - Social Well-being (toxicity, physical appearance, workplace stigma, social stigma) - Financial Support - Role of support groups <p>Clinician's Perspective:</p> <ul style="list-style-type: none"> - What are the side effects/ treatment related issues that can be managed at home? - Alternative therapies/ treatment? - Empathy vs sympathy - Palliative care/ end of life care

11.30 AM – 12.00 PM	Evolving Lung Cancer Treatment: clinical research and role of NGOs/PAGs	Chairperson/Moderator: Dr. Vanita Noronha Speaker: Dr. Sewanti Limaye, Ms. Vandana Gupta, Mr. Vivek Tomar A Fire Chat conversation	Giving a future perspective of Lung Cancer treatment evolution and how PAGs can play an important role in Clinical research (Newer medicines vs affordability)
12.00 PM – 1.10PM	Workshop & Presentation Co - creating future of Lung Connect to reach out to patients & Caregivers across the country. Designing Strategy and Plan	Mentors Group 1 Dr. K V Ganpathy, Ms. Kavita Mishra Group 2 Ms. Nirjari Dalal, Ms. Himadri Nahak, Group 3 Ms. Ruby Ahluwalia Mr. Vivek Sharma Group 4 Dr. Anand Parihar, Dr. Vandana Dhamankar	Group 1 – Using Lung Connect Digital Platforms to spread awareness Group 2 - Using Lung Connect Digital Platforms to increase disease education Group 3 - How Lung Connect as a platform can be replicated beyond Tata Mumbai to support more patients and caregivers? Group 4: How Lung Connect can become a unified voice of Lung Cancer community in India as a formal structured body? Participants will be divided into 4 subgroups and will brainstorm and will come up with scalable and sustainable solutions (30 minutes for brainstorming followed by 10 minutes of presentation for each group)
1.10 PM – 1.40 PM	Expert Panel – Strategy and plan Presentations	Chairpersons: Dr. Amit Joshi Mr. Venkataramanan R. Panelists: Dr. Ajay Kumar Singh, Mr. Anil Nair, Ms. Bhavisha Sandhya, Mr. Girish Nair, Mr. Prabhat Sinha	Sustaining Impact of Lung Connect
1.40PM – 1.50PM	Cancer burden outside government Setup	Dr. Bharat Singh Bhosle	
1.50PM - 2.00 PM	Way Forward and summary followed by Lunch	Dr. Ajay Singh	
06th Annual Year End Review in Lung Cancer			
NOVEL APPROCHES; UPDATES AND PERSPECTIVE FOR LUNG CANCER NURSING			
DATE: 15th DECEMBER '2022			
Time	Topic	Speaker	
3:00-3:15	Introduction of the theme	Ms. Shweta Ghag, Mumbai	
3:15-3:35	Promoting Early Diagnosis of Lung Cancer	Ms. Jyoti Patel, Mumbai	
3:35-3:55	Challenges in Diagnosis and Treatment of Lung Cancer	Dr Ajay kumar Singh, Mumbai	

3:55-4:15	Advances in Radiation Therapy in Treatment of Lung Cancer	Dr Anil Tibdewal, Mumbai
4:15-4:35	Early Palliative Care for Patients with Lung Cancer	Gauri Punekar, Mumbai
4:35-4:55	Oncologic Thoracic Emergencies of Patients with Lung Cancer	Ms Vaishali Raut, Mumbai
4:55-5:15	Strides in Supportive Care.	Support Group
Radiology Workshop		
Date: 15th December 2022		
Time: 06:30 -08:30 PM		
Time	Topic	Speaker
6:25-6:30PM	Welcome & Introduction	
Screening and Staging		
6:30-6:42PM	Screening and Early Diagnosis of Lung Cancer - Where Do We Stand	Dr. Bhavin Jankharia
6:42-6:54PM	Differene Spectrum of Lung Cancer Presentation	Dr. Soujanya Myanalli
6:54-7:06PM	Anatomical Imaging of NSCLC	Dr. Mandeep Garg
7:06-7:18PM	Metabolic Imaging of NSCLC	Dr. Indraje Dev
7:18-7:30PM	Recent Developments on Molecular Diagnosis of Lung Cancer	Dr. Rajiv Kaushal
7:30-7:40 PM	Q&A	
New Roads in Interventional Oncology		
7:40-7:50PM	Image-Guided Tissue Sampling	Dr. Kunal Gala
7:50-8:00PM	What's New in Thoracic Intervantional Oncology	Dr. Nitin Shetty
8:00-8:05PM	Q&A	
Response Assessment, AI and Multidisciplinary Tumor Board		
8:05-8:15PM	Chemotherapy, Targeted Therapy and Immuno Therapy: How to Access Response	Dr. Jinita Majithia
8:15-8:25PM	Current Practice and Emerging Breakthroughs in AI-Imaging/Radiomics in Lung Cancer	Dr. Amit Choudhari
8:25-8:35PM	Practice Updates in Lung Cancer Imaging: Guidelined and Research	Dr. Nivedita Chakraborty
8:35-8:40PM	Q&A	
Panel Discussion:		
8:40-9:10PM	Lung Cancer Case Management: Evolving Role of Multitmodality and Multidisciplinary Decisions in Lung Cancer	
	Moderator:	Dr. Amit Janu
	Panelists:	Dr. Nivedita Chakraborty
		Dr. Kunal Gala
		Dr. Sayak Choudhary

		Dr. Virendra Tiwari	
		Dr. Naveen Mummadi	
		Dr. Rajiv Kaushal	
		Dr. Vijay Patil	

06th Annual Year End Review in Lung Cancer

GERIATRIC WORKSHOP

DATE: 17th December 09:00-03:00pm

Time	Topic	Things to be Covered	Speaker
8:50am-9:00am	Welcome		Dr. Vanita Naroha Professor, Medical Oncology Tata Memorial Hospital Mumbai
9:00-9:15am	Screening	G8, VES13, fTRST, Rockwood frailty scale: Go through the scales, the cut-offs for normal and abnormal	Dr. Akhil Kapoor Associate Professor, Medical Oncology Tata Memorial Hospital Varanasi
9:15-9:20am	Audience questions and answers		
9:20-9:45am		Hands-on calculation	
9:45-10:10am	Function/falls	ADL, IADL, Falls, TUG, SPPB, POMA, Handgrip strength: Scales, methodology for testing, cut-offs	Dr. Sarika Mahajan Physiotherapist (Scientific assistant) Tata Memorial Hospital Mumbai
10:10-10:15am	Audience questions and answers		
10:15-10:45am		Hands-on calculation	
10:45-10:55am	BREAK/MEET THE PROFESSOR		
10:55-11:15am	Nutrition	Weight loss, BMI, MNA, skin thickness, SARC-F	Dr. Purabi Mahajan Senior Dietician Tata Memorial Hospital Mumbai
11:10-11:15am	Audience questions and answers		
11:15-11:45am		Hands-on calculation	
11:45-12:05pm	Medications	Polypharmacy, Beers, Start and Stopp (definitions, scales, cutoffs, interpretations), Drug Interactions	Dr. Vikram Gota Professor, Department of Clinical Pharmacology Advanced Centre for Treatment Research & Education in Cancer (ACTREC) Mumbai
12:05-12:10pm	Audience questions and answers		
12:10-12:40pm		Hands-on assessment	
12:40-1:00pm	Psychology	GDS, GAD7	Dr. Lekhika Sonkusare Psycho oncologist Tata Memorial Hospital Mumbai
1:00-1:05pm	Audience questions and answers		
1:05-1:35pm		Hands-on assessment	
1:35-2:00pm	LUNCH BREAK		
2:00-2:30pm	Cognition	Screening, MMSE, MOCA, ACE	Dr. Abhijith Rao Senior Resident, Medical Oncology Tata Memorial Hospital Mumbai
2:30-2:35pm	Audience questions and answers		
2:35-3:05pm		Hands-on assessment	

18-Dec-22 (Day 2)

06th Annual Year End Review in Lung Cancer			
GERIATIC WORKSHOP			
DATE: 18th December 09:00-12:00pm			
Time	Topic	Things to be Covered	Speaker
9:00-9:15am	Life expectancy calculation	e-prognosis Lee Schonberg	Dr. Enrique Soto Medical Oncologist National Institute of Medical Science and Nutrition Mexico City
9:15-9:20am	Audience questions and answers		
9:20-9:35am		Hands-on assessment	
9:35-9:55am	Chemotoxicity calculation	CARG, CRASH	Dr. Anant Ramaswamy Professor Tata Memorial Hospital Mumbai
9:55-10:00am	Audience questions and answers		
10:00-10:20am		Hands-on assessment	
10:20-10:45am	Social support	OARS MSS, Caregiver burden	Dr. Anita Kumar Fellow in Geriatric Oncology Tata Memorial Hospital Mumbai
10:45-10:50am	Audience questions and answers		
10:50-11:10am		Hands-on assessment	
11:10-11:25am	Fatigue	NRS, Mob-T, Mob-H (scales, cutoffs)	Dr. Manjusha Vagal Officer in-charge, Occupational therapist Tata Memorial Hospital Mumbai
11:25-11:30am	Audience questions and answers		
11:30-11:40am		Hands-on assessment	Dr. Vanita Naroha Professor, Medical Oncology Tata Memorial Hospital Mumbai
11:40-12:00am	Interpretation and intervention		
MOLECULAR WORKSHOP Hall B			
DATE: 17th December 03:00-08:00pm			
Time	Topic	Speaker	
03:00-03:05pm	Welcome & Introduction	Dr Anuradha Choughule	
03:05-03:35pm	Panel Discussion: Diagnostic Approaches and treatment in Early NSCLC		
	Moderator	Dr Sabita Jiwnani, Mumbai	
	Panelists	Dr Aparna Dhar, Delhi	
		Dr Trupti Pai, Mumbai	
		Dr Hitesh Goswami	
		Dr Vanita Noronha	
		Dr Amit Janu	
		Dr Akhil Kapoor	
03:35-04:05pm	Panel Discussion: Precision targeted care to overcome failure in early late and metastatic lung cancer.		
	Moderator	Dr T P Sahoo, Bhopal	
	Panelists	Dr Vijay Patil	

		Dr Vamshi Krishna
		Dr Amit Dutt
		Dr Rajeev Kaushal
		Dr Amit Verma
	Session Sponsored By Astrazeneca	
04:05-04:35pm	Biomarker testing in NSCLC - How have we changed over the decade?	
	Moderator	Dr Ullas Batra, Delhi
	Panelists	
		Dr Akhil Kapoor
		Dr Vidya Harini
		Dr Srujana Dutt
		Dr Ajay Kumar Singh
		Dr Moitri Basu
		Dr Amit Dutt
	Chairperson: Dr Chetan Deshmukh	
04:35-04:50pm	Fusion genes and their targeted therapies in Lung Adenocarcinoma: FISH,IHC, NGS	Dr Rajeev Kaushal
04:50-05:05pm	Driver actionable mutations by Liquid Biopsy	Dr Amit Verma, Delhi
05:05-05:15pm	role of epigenetics in lung cancer	Dr Koustav Sarkar
05:15-05:25pm	ABC transporters in lung cancer	Dr Siddharth Sharma
05:25-05:35pm	cfDNA based EGFR test in NSCLC	Ms Vichitra Behel
05:35-05:45pm	small cell transformation in lung cancer	Dr Nalini Gupta
05:45-05:55pm	genomic sequencing and therapeutics in India	Dr Aju Mathew, Vellore
05:55-06:05pm	Circulating Tumor Cells in NSCLC	Dr Jayant Khandare
06:05-06:15pm	Circulating Tumor Cells in Small Cell Lung Cancer	Dr Prashant Kumar (Karkinos)
	Chairperson- Dr Purvish Parikh	
	Data Presentation: Biomarkers in Lung Cancer by NGS	
06:15-06:25pm	SRL Lab	Dr Aparna Dhar, Delhi
	Session Sponsored By Guardant 360	
06:25-06:35pm	TBC	Dr Kumar Prabhaskar, Mumbai
06:35-06:45pm	Medgenome lab	Dr Ramprasad
	Session Sponsored By 4Base Care	
06:45-06:55pm	TBC	Dr Vidya Veldore, Bengaluru
06:55-07:05pm	One Celldx	Dr Gouhar
	Foundation One	
07:05-07:15pm	TBC	TBC

07:20pm Onwards	Closing Remarks	Dr Vjay Patil Dr Kumar Prabhaskh
Radiation Workshop		
Lung SBRT and Lung with Brain Metastases SRS		
18 Dec Hall B Time - 09:00 - 12:00pm		
Time	Topic	Speaker
9:00-9:05 AM	Introduction and overview of 2nd edition	Dr Trinanjan Basu Senior Consultant, Radiation Oncologist HCG Cancer Centre Mumbai
	Chairpersons	Dr S K Srivastava, Director Radiation oncology HCG, Colaba, Mumbai Dr Sharmila Aggarwal Senior Radiation Oncologist Jaslok Hospital Mumbai Dr. Sandip De Senior Consultant Radiation Oncology Apollo Hospital, Mumbai
9:05-9:20 AM	Summary of Lung SBRT lectures of 1st edition	Dr. Naveen Mummadi Associate Professor, Department of Radiation Oncology Tata Memorial Centre, Mumbai
9:20-10:20 AM	Lung SBRT- Practical aspects- Case based	Moderator- Dr Anil Tibdewal Assistant Professor Radiation Oncology Tata Memorial Centre, Mumbai
	Panelist	Dr Shyam Bisht Associate Director, Radiation Oncology Medanta Cancer Institute Medanta- The Medicity, Gurgaon Dr Pranav Chadda, Consultant Radiation Oncologist Kokilaben Dhirubhai Ambani Hospital & Research Centre Mumbai
		Dr. C. Anand Narayan Chief Of Radiation Oncology G.Kuppusamy Naidu Memorial Hospital Coimbatore
		Dr. Moses Arunsingh, Consultant Clinical Oncologist, Tata Medical Center, Kolkata
		Dr Sayan Das Consultant, Radiation Oncology Kolkata - Narayana Superspeciality Hospital, Kolkata

		Dr Shikha Goyal Assistant Professor (Radiotherapy) PGIMER, Chandigarh	
		Dr Madhu Sairam Consultant Radiation oncologist Kovai Medical Center and Hospitals, Coimbatore	
		Mr Ratheesh Nair Medical Physicist and RSO HCG, Borivali	
		Mr Sijin Sebastian HCG cancer center, Mumbai	
10:20-10:45 AM	Challenges in Lung SBRT program Requirements related. Practical challenges. Steps in implementations.	Moderator: Dr Shirley Lewis Associate Professor Department of Radiotherapy and Oncology Manipal Comprehensive Cancer Care Centre Kasturba Medical College Manipal	
	Panelist	Dr Birendra kumar Yadav Medical Director Purbanchal Cancancer Hospital Birtamode, Nepal	
		Dr Anis Bandyopadhyay Associate Professor NRS Medical College, Kolkata	
		Dr Vaibhav Sonwani Senior Consultant, Radiation Oncologist HCG, Nagpur	
		Dr Deepak Gupta Consultant Radiation Oncologist Medanta Cancer Institute Gurugram	
		Dr Pooja Nandwani Patel Sr. Consultant & Head Sterling Cancer Hospital, Ahemdabad	
		Dr Bhooshan Zade Director and Sr Consultant, Department of Radiation Oncology, Ruby Hall Clinic Cancer Center, Pune	
		Dr. A.Pichandi Director , Central Physics Health Care Global Ent. Ltd, Bengaluru	
		Mr.Prakash Umbarkar Sr. Radiation Therapist P.D Hinduja Hospital, Mumbai	
		Dr Nikesh H Consultant radiation oncologist Kokilaben hospital mumbai	
10:45-11:00 AM	Summary of Lung with brain mets lectures from 1st edition	Dr Upasna Saxena Senior Consultant Radiation Oncologist HCG Cancer Centre, Mumbai	
11:00-11:50 AM	Lung with brain mets- SRS/FSRS practical aspects- Case based	Moderator: Dr Kaustav Talapatra Director - Radiation Oncology Nanavati Max Superspeciality Hospital, Mumbai	

	Panelist	Dr Ashu Abhishek Additional Director Radiation Oncology, FMRI Gurugram
		Dr Sridhar P S, Senior Consultant Radiation Oncology HCG, Bangalore
		Dr Nikhil Kalyani Consultant Radiation Oncologist Jaslok Hospital, Mumbai
		Dr Sumeet Basu Head, Department of Radiation Oncology Kokilaben Dhirubhai Ambani Hospital Mumbai
		Dr Saurabha Kumar Consultant and Head, Department of Radiation Oncology Narayana Health City, Bangalore
		Mr. George Biju V Technical Officer Dept of Radiation Oncology, Tata Memorial Hospital, Mumbai
		Dr. A.Pichandi Director , Central Physics Health Care Global Ent. Ltd, Bengaluru
		Dr Amol Kakade, Mumbai
11:50-12:00 PM	Closing remarks/ Key points	Dr J P Aggarwal Professor and Head, Department of Radiation Oncology, Tata Memorial Hospital, Mumbai
06th Annual Year End Review In Lung Cancer		
NOVEL APPROCHES; UPDATES AND PERSPECTIVE FOR LUNG CANCER NURSING		
DATE: 18th DECEMBER '2022 12:00-02:00pm Hall C		
Time	Topic	Speaker
12:00-12:10pm	Welcome & Introduction	Dr Shamali Poojary
	Moderator	Dr Prajakta Bhagat
12:10-12:40pm	Changing Needs Requires Change In Palliative Care Approach	Dr. Jyothsna Kuriakose
12:40-01:10pm	Psycho-Social Impact On Patients And Caregivers	Dr. Somitra Datta
01:10-01:30pm	Financial Toxicity In Advanced Lung Cancer	Dr K V Ganpathy
01:30-01:50pm	Panel Discussion: Survivorship In Advanced Lung Cancer- A Brainstorming Session	
	Moderator:	Dr Shreya Nair
	Panelist:	Dr Pallavi Singh
		Dr Avinash Tiwari
		Dr Nandini Menon
		Dr Virendra Tiwari

01:50-02:00pm	Wrap Up And Take Home Messages	Dr Jayita Deodhar
06th Annual Year End Review in Lung Cancer		
16th December 2022		
Time	Topic	Speaker
09:00am Onwards	Welcome & Introduction	Dr. Priya Eshpuniyani, Mumbai
	Session Cordinator	Dr. Priya Eshpuniyani, Mumbai
	Chairperson	Dr. B K Mishra, Varanasi
	Early Stage Lung Cancer	
	Local Therapy Issues	
09:00-09:07am	Segmentectomy Versus Lobectomy In Small-Sized Peripheral Non-Small-Cell Lung Cancer: A Multicentre, Open-Label, Phase 3, Randomised, Controlled, Non-Inferiority Trial	Dr. Prashant Penamadu, Pondicherry
09:07-09:14am	Vascular Invasion Identifies The Most Aggressive Histologic Subset Of Stage I Lung Adenocarcinoma: Implications For Adjuvant Therapy	Dr. Durgatosh Pandey, Varanasi
09:14-09:21am	A Systematic Review Into The Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) In Patients With Non-Small Cell Lung Cancer (NSCLC)	Dr. Amit Janu, Mumbai
09:21-09:28am	Chest CT Scan Plus X-Ray Versus Chest X-Ray For The Follow-Up Of Completely Resected Non-Small-Cell Lung Cancer : A Multicentre, Open-Label, Randomised, Phase 3 Trial	Dr. Virendra Tiwari, Mumbai
09:28-09:35am	Lobar Versus Sublobar Resection In The Elderly For Early Lung Cancer: A Meta-Analysis	Dr. Priya Eshpuniyani, Mumbai
09:35-09:42am	Robotic-Assisted Versus Video-Assisted Thoracoscopic Lobectomy: Short-Term Results Of A Randomized Clinical Trial (RVLOB Trial)	Dr. Saravana R, Nammakal
09:42-09:49am	Comparison Of Stereotactic Body Radiotherapy And Radiofrequency Ablation For Early-Stage Non-Small Cell Lung Cancer: A Systematic Review And Meta-Analysis	Dr. Anil Tibdewal, Mumbai
09:50-10:20am	Panel Discussion : Local Therapy Issues	
	Moderator:	Dr. Arvind Krishnamurthy, Chennai
	Panelists:	Dr. Devayani Niyogi, Mumbai
		Dr. Simit Siphkota, Nepal
		Dr. Jacob George, Goa
		Dr. Shoaib Zaidi, Delhi
	Session Cordinator:	Dr. Amit Kumar, Patna
	Chairperson:	Dr. N T Awad, Mumbai
	Adjuvant Systemic Therapy: TKI	
	Session Sponsored By: Astrazeneca	
10:20-10:35am	Osimertinib As Adjuvant Therapy In Patients With Resected EGFRm Stage Ib Iiia NSCLC- Updated Results From ADAURA	TBC

10:35-10:42am	Adjuvant Icotinib Versus Observation In Patients With Completely Resected, EGFR-Mutated, Stage IB Non-Small Cell Lung Cancer: A Randomized Phase II Trial.	Dr. Rushabh Kothari, Ahmedabad
10:42-10:49am	Randomized Phase III Study Of Gefitinib Versus Cisplatin Plus Vinorelbine For Patients With Resected Stage Ii-Iiia Non-Small-Cell Lung Cancer With EGFR Mutation (Impact)	Dr. Mansi Sharma, Delhi
10:49-10:56am	Aumolertinib As Adjuvant Therapy In Postoperative EGFR-Mutated Non-Small Cell Lung Cancer	Dr. Manu Prasad, Kerala
10:56-11:03am	Patients' Preferences For Adjuvant Osimertinib In Non-Small Cell Lung Cancer (NSCLC)	Dr. Anup Toshniwal, Aurangabad
11:03-11:10am	Updated Overall Survival And Exploratory Analysis From Randomized, Phase Ii Evan Study Of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy In Stage Iiia Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer	Dr. Abhinav Zawar, Aurangabad
11:10-11:40am	Panel Discussion : Adjuvant Systemic Therapy-TKI	
	Moderator:	Dr. Navneet Singh, Chandigarh
	Panelists	Dr. Vanita Noronha, Mumbai
		Dr. Vijay Sharnangat, Mumbai
		Dr. Vasu Babu, Vijayawada
		Dr. Mansi Sharma, Delhi
		Dr. Kunal Jobanputra, Mumbai
		Dr. Ajay Kumar Singh, Mumbai
	Session Cordinator	Dr. Akhil Kapoor, Varanasi
	Adjuvant/Neoadjuvant Systemic Therapy-IO	
11:42-11:49am	Adjuvant Atezolizumab After Adjuvant Chemotherapy In Resected Stage Ib-Iiia Non-Small-Cell Lung Cancer (Impower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial	Dr. Padmaj Kulkarni, Pune
11:49-11:56am	Pembrolizumab Versus Placebo As Adjuvant Therapy For Completely Resected Stage Ib-Iiia Non-Small-Cell Lung Cancer (Pearls/Keynote-091): An Interim Analysis Of A Randomised, Triple-Blind, Phase 3 Trial	Dr. Sangeetha P, Vizag
11:56-12:03am	Neoadjuvant Nivolumab Plus Chemotherapy In Resectable Lung Cancer	Dr. Alok Goel, Sangrur
12:03-12:10am	Pathologic Complete Response (PCR) After Neoadjuvant (Neoadj) Chemoimmunotherapy (Chemo+Io) In Resectable Non-Small Cell Lung Cancer (NSCLC): A Systematic Review And Pooled Analysis	Dr. Jacob George, Goa
12:10-12:17pm	Neoadjuvant Nivolumab In Early-Stage Non-Small Cell Lung Cancer (NSCLC): Five-Year Outcomes	Dr. Siddhartha Turkar, Raipur
12:17-12:24pm	Neoadjuvant Nivolumab (Nivo) + Platinum-Doublet Chemotherapy (Chemo) Versus Chemo For Resectable (Ib-IIIa) Non-Small Cell Lung Cancer (NSCLC): Association Of Pathological Regression With Event-Free Survival (EFS) In Checkmate 816.	Dr. Sudeep Das, Kolkata
12:24-1:09pm	Panel Discussion : Adjuvant/Neoadjuvant Systemic Therapy-IO	
	Moderator	Dr. Ashish Singh, Vellore

	Panelists	Dr. Ramakant Deshpande, Mumbai
		Dr. Vanita Noronha, Mumbai
		Dr. George K, Mumbai
		Dr. Suresh Babu, Bengaluru
		Dr. Ashish Bakshi, Mumbai
		Dr. Virendra Tiwari, Mumbai
1:09-1:54pm	Lunch Break	
	Session Cordinator	Dr. Nandini Menon, Mumbai
	Driver Mutation Part 1: EGFR	
	First Line EGFR or Lung Term Data	
1:54-2:01pm	Bevacizumab Plus Erlotinib Versus Erlotinib Alone In Japanese Patients With Advanced, Metastatic, Egfr-Mutant Non-Small-Cell Lung Cancer (Nej026): Overall Survival Analysis Of An Open-Label, Randomised, Multicentre, Phase 3 Trial (Jan 2022)	Dr. Arvind Kumar, Patna
2:01-2:08pm	Furmonertinib Versus Gefitinib In Treatment-Naïve EGFR Mutated Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Multi-Center, Phase III Study (Furlong)	Dr. Rajesh Patidar, Indore
2:08-2:15pm	Oritinib (Sh-1028) A Third-Generation EGFR Tyrosine Kinase Inhibitor In Locally Advanced Or Metastatic NSCLC Patients With Positive EGFR T790m: Results Of A Single-Arm Phase II Trial	Dr. Kiran Tamkhane, Mumbai
2:15-2:22pm	Updated Analysis Of Nej009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy For Non-Small-Cell Lung Cancer With Mutated EGFR	Dr Kunal Jobanputra, Mumbai
2:22-2:29pm	Randomized Trial Of First-Line Tyrosine Kinase Inhibitor With Or Without Radiotherapy For Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer	Dr. Rakesh Pinninti, Hyderabad
2:29-2:36pm	Sintilimab In Combination With Anlotinib In Non-Small Cell Lung Cancer Patients With Uncommon EGFR Mutations: A Phase Ii, Single-Arm, Prospective Study	Dr. Birendra, Nepal
2:36-3:06pm	Panel Discussion: First Line EGFR Or Long Term Data	
	Moderator	Dr. Krupa Shankar, Coimbatore
	Panelists	Dr. Kumar Prabhash, Mumbai
		Dr. Sunny Jandyal, Jammu
		Dr. Vanita Noronha, Mumbai
		Dr. Pratik Chandrani, Mumbai
		Dr. Nandini Menon, Mumbai
	Session Sponsored by: Astrazeneca	
3:06-3:31pm	Case Based Panel Discussion – Advanced EGFRm NSCLC	
	Session Cordinator	Dr. Ajay Kumar Singh, Mumbai
	Overcoming Resistance to TKI	
3:31-3:38pm	Simultaneous Tissue And Liquid Next-Generation Sequencing After First-Line EGFR Tyrosine Kinase Inhibitors Resistance In Advanced Non-Small Cell Lung Cancer	Dr. Sunil Pasricha, Delhi

3:38-3:45pm	Real-World Landscape Of EGFR C797x Mutation As A Resistance Mechanism To Osimertinib In Non-Small Cell Lung Cancer	Dr. Amit Kumar, Patna
3:45-3:52pm	A Phase II Study Of Atezolizumab In Combination With Bevacizumab, Carboplatin Or Cisplatin, And Pemetrexed For EGFR-Mutant Metastatic NSCLC Patients After Failure Of EGFR TKIs	Dr. Sameer Shrirangwar, Nagpur
3:52-3:59pm	Durvalumab + Chemotherapy In Patients (Pts) With Advanced EGFR Mutation-Positive (EGFRm) Nsclc Whose Disease Progressed On First-Line (1l) Osimertinib: An Orchard Study Interim Analysis	Dr. Ajay Kumar Singh, Mumbai
3:59-4:06pm	A Randomised Phase Ii Study Of Osimertinib And Bevacizumab Versus Osimertinib Alone As Second-Line Targeted Treatment In Advanced NSCLC With Confirmed EGFR And Acquired T790m Mutations: The European Thoracic Oncology Platform (Etop 10-16) Booster Trial	Dr. Sunil Chopade, Mumbai
4:06-4:13pm	Capmatinib Plus Osimertinib Vs Platinum-Pemetrexed Doublet Chemotherapy As Second-Line Therapy In Patients With Stage Iiib/Iiic/Iv EGFR-Mutant, T790m-Negative, Met-Amplified NSCLC	Dr. Sunit Lokwani, Indore
4:13-4:20pm	Highly Effective 4th Generation EGFR-Tki, Targeting EGFR C797s Triple Mutation In NSCLC	Dr. Nandini Menon, Mumbai
4:20-4:27pm	A 4th Generation EGFR Tki, For Progressed NSCLC After EGFR Tki Therapy: Pk, Safety And Efficacy From Phase 1 Study	Dr. Dilip Vallathol, Callicut
4:27-4:34pm	Optimization Of Treatment Options For EGFR-Mutant, Stage III, Unresectable NSCLC: A Systematic Review And Meta-Analysis	Dr. Shivam Shingla, Mumbai
4:34-5:04pm	Panel Discussion : Overcoming Resistance To TKI	
	Moderator	Dr. Vamshi Krishna, Hyderabad
	Panelists	Dr. Bharat Bhosale, Mumbai
		Dr. Aditya Kanteti, Mumbai
		Dr. Murtaza Bohra, Nagpur
		Dr. Vidya Veldore, Bengaluru
		Dr. Dilip H Vallathol, Callicut
		Dr. Amit Kumar, Patna
		Dr. Akhil Kapoor, Varanasi
	SCLC	
5:04-5:11pm	Once Daily (Od) Versus Twice-Daily (Bid) Chemoradiation For Limited Stage Small Cell Lung Cancer (Ls-Sclc): A Meta-Analysis Of Randomized Clinical Trials	Dr. Deepanjali Adulkar, Mumbai
5:11-5:18pm	Adebrelimab Or Placebo Plus Carboplatin And Etoposide As First-Line Treatment For Extensive-Stage Small-Cell Lung Cancer (Capstone-1): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial	Dr. Manoj Mahajan, Udaipur
5:18-5:25pm	Effect Of First-Line Serplulimab Vs Placebo Added To Chemotherapy On Survival In Patients With Extensive-Stage Small Cell Lung Cancerthe Astrum-005 Randomized Clinical Tria	Dr. Ashay Karpe, Mumbai
5:25-5:32pm	Phase 2 Study Analysis Of Talazoparib (Tala) Plus Temozolomide (Tmz) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	Dr. Amit Joshi, Mumbai

5:32-5:39pm	Comparison Of Quality Of Life In Patients Randomized To High-Dose Once Daily (Qd) Thoracic Radiotherapy (Trt) With Standard Twice Daily (Bid) Trt In Limited Stage Small Cell Lung Cancer (LS-SCLC) On CALGB 30610	Dr. Kinjal Jani, Ahmedabad	
5:39-5:46pm	Kyscraper-02: Primary Results Of A Phase Iii, Randomized, Double-Blind, Placebo[1]Controlled Study Of Atezolizumab (Atezo) + Carboplatin + Etoposide (Ce) With Or Without Tiragolumab (Tira) In Patients (Pts) With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).	Dr. Arun Chandrashekhra, Kochi	
	Session Sponsored By: Astrazeneca		
5:46 -6:06pm	Case Based Panel Discussion - Management Of 11 ES-SCLC		
	Moderator	Dr Sumant Gupta, Delhi	
	Panelists	Dr Srinivas K G	
		Dr Vivek Aggarwala, Kolkata	
		Dr Vijay Aggarwal, Bangalore	
		Dr Sameer Shrirangwar, Nagpur	
		Dr M V Chandrakanth, Kolkata	
	MODERATORS:	Dr. V Kannan, Mumbai	
		Dr. Rajesh Mistry, Mumbai	
	Lung Year End Review -Oration - Honouring The Best In Oncology		
6:06-6:51pm	Prof SD Banavali		
7:00-8:30	ISP PROGRAM (INTAS PHARMA)		
	06th Annual Year End Review in Lung Cancer		
	17th December 2022		
Time	Topic	Speaker	
9:00am Onwards	Welcome & Introduction	Dr. Ashay Karpe, Mumbai	
	Chairperson	Dr. Roshni Pandey, Jabalpur TBC	
	Locally Advance Lung Cancer		
	Local Therapy- Locally Advanced		
09:00-09:07am	Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity- score matched analysis	Dr. Naveen Mummudi, Mumbai	
09:07-09:14am	Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC	Dr Mohit Sharma, Delhi	
09:14-09:21am	Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era	Dr. Nikhil Kalyani, Mumbai	
09:21-09:28am	Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020	Dr. Kaustav Talapatra, Mumbai	
09:28-09:53am	Panel Discussion		
09:28-09:53am	Moderator: Local Therapy- Locally Advanced	Dr.. Anil Tibdewal, Mumbai	
	Panelists:	Dr.. Nikhil Kalyani, Mumbai	

		Dr. Roshni Pandey, Jabalpur
		Dr. Bhavin Visariya, Mumbai
		Dr. Deepanjali Adulkar , Mumbai
		Dr. Vivekanand, Mumbai
	Chairperson :	Dr. K Pavitran, Kochi Dr. Girija Nair, Mumbai
	Neoadjuvant IO Therapy in Locally Advanced	
09:53-10:00am	Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.	Dr. Bhavesh Poladia, Nammakal
10:00-10:07am	Overall Survival & Biomarker Analysis of Neoadjuvant Nivolumab plus Chemotherapy in Operable Stage IIIA Non Small Cell Lung Cancer (Nadim Phase II Trial)	Dr. Bhavesh Parikh, Ahmedabad
10:07-10:14am	Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial	Dr. Amol Dongre, Nagpur
	IO Consolidation Post CRT	
10:14-10:21am	Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study	Dr. Minit Shah, Mumbai
10:21-10:28am	Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.	Dr. Vijay Patil, Mumbai
	Session Sponsored By Astrazeneca	
10:28-10:35am	Real World Evidence of Durvalumab in Stage III NSCLC – PACIFIC-R	Dr. Raajit Chanana, Delhi
10:35-10:42am	Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on durvalumab eligibility and safety profile	Dr.. Srinivas Chilukuri, Chennai
10:42-10:49am	Concurrent versus sequential immune checkpoint inhibition in stage III NSCLC patients treated with chemoradiation	Dr. Amit Aggarwal, Raipur
10:49-10:56am	Impact of grade ≥ 2 pneumonitis (G2+ PNS) on patient reported outcomes (PROs) with durvalumab (D) after chemoradiotherapy (CRT) in unresectable stage III NSCLC	Dr. Simit Sapakota, Nepal
10:56-11:03am	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab	Arun Chandrashekharan
11:05-11:35am	Panel Discussion	
	Moderator:	Dr. Randeep Singh, Delhi
	Panelists:	Dr. Bharat Chauhan, Mumbai
		Dr. Shashank Das, Khargar
		Dr. Prahlad Elamarthi, Bangalore
		Dr.. Dipalee Borade, Mumbai
		Dr.. Biren, Nepal
		Dr.. Vipul Doshi, Solapur

Session Sponsored By Astrazeneca		
11:35-12:00pm	Optimal Management of stage III unresectable NSCLC - Case Based Discussion	
	Moderator	Dr Deepak Koppaka, Hyderabad
	Panelists	Dr Akhil Kapoor, Varanasi
		Dr Anil Tibdewal, Mumbai
		Dr Tarachand Gupta, Jaipur
		Dr Ramakant Deshpande, Mumbai
		Dr Raajit Chanana, Delhi
		Dr Arun Chandrashekhra, Kochi
		Dr Chakor Vora, Pune
Session Sponsored By BMS		
12:00-12:10pm	Dual Checkpoint Inhibitors in 1st Line NSCLC	Dr Vamshi Krishna, Hyderabad
	Session Coordinator	Dr. Sudeep Das, Kolkata
	Chairperson	Dr. Smita Gupte, Nagpur
	Immunotherapy	Dr. Sameer Nanaware, Mumbai
	First line IO or Long term IO data	
12:10-12:17pm	Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score $\geq 50\%$: KEYNOTE-598 3-year follow-up	Dr. Kishore Kota, Vishakhapanam
12:17-12:24pm	The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C	Dr. Arif Khan, Hyderabad
12:24-12:31pm	Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.	Dr. Rakesh Boya Reddy, Vizag
12:31-12:38pm	Pembrolizumab versus best supportive care survival outcomes in ECOG performance status 2 NSCLC patients	Dr. Peush Bajpai, Delhi
12:38-12:45pm	Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data	Dr. Rohit Swami, Jaipur
12:45-12:52pm	Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation	Dr. Kripa Bajaj, Hyderabad
12:52-01:00pm	IPSOS: Results from a Phase III Study of first line(1L) atezolizumab vs single agent chemotherapy in patients with NSCLC non Eligible for a platinum containing regimen	Dr. Adwaita Gore, Mumbai
01:00-01:07pm	Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study	Dr. Chitresh Aggarwal, Panchkula
01:07-01:14pm	Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer	Dr.. Gautam Goyal, Chandigarh

01:14-01:21pm	Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy	Dr. MV Chandrakanth, Kolkata
01:21-01:28pm	Camrelizumab monotherapy or plus apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study	Dr. Taha Sethjiwala, Indore
01:28-01:35pm	Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy	Dr. Satvik Khaddar, Indore
01:35-02:10pm	Panel Discussion :	
	Moderator:	Dr. T P Sahoo, Bhopal
	Panelists:	Dr. Kumar Prabhash, Mumbai
		Dr. Tarachand Gupta, Jaipur
		Dr. Kshitij Joshi, Mumbai
		Dr. MV Chandrakanth, Kolkata
		Dr. Nandini Menon, Mumbai
02:10-02:50pm	Lunch Break	
02:10-02:50pm	Session Coordinator	Dr. Chakor Vora, Pune
	Chairpersons	Dr. Sunil Kr Gupta, Delhi
	Post IO progression	Dr. S P Rai, Mumbai
02:50-02:57pm	Phase II Randomised Study of Ramucirumab & Pembrolizumab Versus Standard of care in Advanced Non Small Cell Lung Cancer Previously Treated with Immunotherapy - Lung MAP S1800A	Dr. Bharat Bhosale, Mumbai
02:57-03:05pm	Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non-small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.	Dr. Nandini Menon, Mumbai
03:05-03:12pm	Results of a phase II study investigating efitlagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts	Dr. Rekha Bansal, Hyderabad
03:12-03:20pm	HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy	Dr. Gunjesh Kumar Singh, Ranchi
03:20-03:27pm	Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer	Dr. Shefali Sardana, Delhi
	Session Sponsored By Roche	
03:30-03:45pm	IMpower010: Adjuvant Atezolizumab after adjuvant chemotherapy in resected stage IB - IIIA non-small cell lung cancer	TBC
03:45-04:15pm	Panel Discussion- Redefining the management of NSCLC with Atezolizumab - Now & Then	
	Moderator	Dr Sewanti Limaye, Mumbai
	Panelists	TBC

	Session Sponsored By MSD	
04:15-04:45pm	Doubling the Fight - IO + Chemo in mNSCLC	Dr Ullas Batra, Delhi
	Low Dose IO & Alternate IO	
04:55-04:55pm	Camrelizumab monotherapy or plus apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study	Dr. Vijay Patil, Mumbai
	Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation	
	Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy	
	Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer	
04:55-05:05pm	Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in Taiwan	Dr. Amol Akhade, Mumbai
	Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study	
	Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer: A Retrospective Case Series	
	Session Coordinator	Dr. Sunil Chopade, Mumbai
	Chairperson	Dr. Anand Pathak, Nagpur
	Exon 20 & Her 2	
05:05-05:12pm	Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer	Dr. Sumant Gupta, Delhi
05:12-05:20pm	TBC	Dr Amol Patel, Mumbai
05:20-05:27pm	Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)	Dr. Ashish Joshi, Mumbai
05:27-05:35pm	Pozitotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial	Dr. Shruti Kate, Nashik
	Session Sponsored By Eli Lilly	
05:35-06:05pm	Cyramza Clinical Evidence In Second Line Lung Cancer	Dr Ullas Batra, Delhi
06:05-06:15pm	Hidden EGFR Threat: Role of Amivantamab	Dr. Vashisth Maniar, Mumbai
06:15-06:35pm	Hidden EGFR Threat: Role of Amivantamab: Panel Discussion	
	Moderator	Dr. Ullas Batra, Delhi
	Panelists	Dr. Vijay Patil, Mumbai
		Dr. PS Dattatreya, Hyderabad
		Dr. Suresh Babu, Bangalore
		Dr. Shruti Kate, Nashik
06:35-07:05pm	Session Sponsored By Pfizer	
	TBC	
	Session Sponsored By BD/Bard	
07:05-07:30pm	Choosing Right VAD in Cancer Patients.	

06th Annual Year End Review in Lung Cancer		
18th December 2022		
Time	Topic	Speaker
09:00am Onwards	Welcome & Introduction	Dr. Nandini Menon, Mumbai
	Session Coordinator	Dr. Vikas Talreja, Kanpur
	Chairpersons	Dr. Abhay Uppe, Mumbai Dr. N K Warriar, Calicut
	ALK/ROS/RET/NTRK/BRAF/	
	BRAF	
09:00-09:07am	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis	Dr. Chakor Vora, Pune
09:17-09:17am	Session Sponsored By: Novartis	
	ALK	
09:17-09:27am	Session Sponsored By: Novartis	
09:27-09:34am	Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results	Dr. Uma Dangi, Mumbai
09:34-09:41am	Clinical implications of cardiotoxicity and pharmacokinetics of alectinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)	Dr. Hollis D Souza, Mumbai
09:41-09:48am	Tumor invasiveness, response to ALK inhibitors and resistance mechanism in NSCLC with different ALK variants	Dr. Vikas Talreja, Kanpur
09:48-09:55am	Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study	Dr. Mridul Malhotra, Delhi
09:55-10:02am	Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse	Dr. N K Warriar, Kolkata
	Session Sponsored By Roche	
10:00-10:30pm	ALESIA study update & Panel Discussion on Optimal Sequencing of ALK inhibitors in ALK+ mNSCLC	
	Moderator:	Dr. Ullas Batra, Delhi
	Panelists:	Dr. NK Warriar, Calicut
		Dr. Ashwin Philip, Ludhiana
		Dr. Rakesh Pinniti, Hyderabad
		Dr. Ashish Singh, Vellore
		Dr. Vishwanath Sathyanarayanan
		TBC
	Session Coordinator	Dr. Hollis Dsouza, Mumbai
	Chairpersons	
	ROS	

11:00-11:07am	The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer	Dr. Pushpak Chirmade, Mumbai
11:07-11:14am	TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors	Dr. Chetan Deshmukh, Pune
11:14-11:21am	Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study	Dr. M V Chandrakanth, Kolkata
	RET	
11:21-11:28am	Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC)	Dr. Somnath Roy, Kolkata
11:28-11:35am	RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions	Dr. Pradeep Ventrapati, Vizag
11:35-11:42am	Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer	Dr. Vikas Talreja, Kanpur
11:42-11:49am	Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial	Dr. Boman Dhabhar, Mumbai
11:50-12:20pm	Panel Discussion: (ROS & RET)	
	Moderator:	Dr. Akhil Kapoor, Varanasi
	Panelists:	Dr. Darshana Rane, Mumbai
		Dr. Uma Dangi, Mumbai
		Dr. Boman Dhabhar, Mumbai
		Dr. Pushpak Chirmade, Mumbai
		Dr. Sonal Dhande, Nashik
	Session Cordinator	
	Chairpersons	
	NTRK	
12:20-12:27pm	Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib	Dr. Pritam Kataria, Mumbai
12:27-12:34pm	Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC	Dr. Sandeep Ishi, Nashik
12:34-12:41pm	Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours	Dr. Shikhar Kumar, Hyderabad
12:41-12:48pm	Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.	Dr. Manu Prasad, Kerala
	MET	
12:48-12:55pm	Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC	Dr. Saswata Saha, Mumbai
12:55-1:02pm	Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy	Dr. Vibhor Sharma, Delhi

1:02-1:09pm	Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1	Dr. Ashish Singh, Vellore	
1:09-1:15pm	Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.	Dr Rushabh Kothari, Ahmedabad	
1:15-1:45pm	Panel Discussion: (NTRK/MET)		
	Moderator:	Dr. Sunil Kr Gupta, Delhi	
	Panelists:	Dr. Chetan Deshmukh, Pune	
		Dr. Rakesh Taran, Indore	
		Dr. Vijay Patil, Mumbai	
		Dr. Suhas Aagre, Mumbai	
		Dr. Pritam Kataria, Mumbai	
		Dr. Kripa Bajaj, Hyderabad	